support keytruda merck post solid outlook
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data aug
rate updat aug
currenc amount express
valuat growth profit
methodolog valu compani
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past five year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-small-cel lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat major drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ solid launch
drug keytruda oncolog follow success
merck shift focu toward area unmet medic need
specialty-car area keytruda lead new direct
expect keytruda leadership non-smal cell lung cancer
key driver growth firm next sever year
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl geograph
perspect close half compani sale gener unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
support keytruda merck post solid outlook
immuno oncolog appear underappreci jul
merck report second-quart result slightli ahead
consensu expect expect
chang fair valu estim base minor
out-performance continu view compani
under-valued larg due bullish expect
cancer drug keytruda almost billion sale
project ahead consensu expect
billion also merck lead posit immuno-oncolog
led keytruda help reinforc wide moat rate
firm
quarter strong keytruda growth
lead total sale growth growth rate
larg continu remaind year
gener pressur heavi brand hepat
competit remain back half year
headwind reced new indic
keytruda continu drive strong growth
drug next sever year particular expect
approv keytruda first-lin squamou non-small-
cell lung cancer oct food drug
administr deadlin european approv use
keytruda combin chemotherapi nsclc
patient regardless express end
year lung cancer expect merck gain
late-stag diseas market cede share roch
bristol smaller biomark diseas area show
express alk/egfr tmb expect
keytruda gain new indic liver cancer
outsid immuno-oncolog major merck
product matur face poor growth prospect
except anesthesia-rel drug bridon hpv
vaccin gardasil intern market anim
healthcar divis show strong growth
quarter continu post steadi gain
next sever year
deeper dive outlook keytruda
competit immuno oncolog drug pleas see report
bristol-my
valuat growth profit jun
increas fair valu estim
per share base strong clinic data cancer drug
keytruda support increas use drug keytruda
key merck valuat expect leader
immuno-oncolog market expect drug reach
peak sale billion larg base strong
efficaci sever cancer type includ lung head
neck melanoma sever cancer indic
look entir compani next decad
expect merck post annual top-lin growth
new drug offset drug lost gener competit
potenti game changer growth rate includ
compani pipelin immuno-oncolog drug move
quickli clinic develop merck still face
gener competit nasonex zetia vytorin
next year howev believ pipelin drug
growth exist drug off-set near-term gener
headwind overal expect larg stabl margin
near term minor improv
specialty-ori drug launch carri strong price
power need less market support
larg base low volatil cash flow
divers inelast product portfolio rate merck
uncertainti low scenario analysi assum
base-cas fair valu estim bull case
probabl bear case probabl
project fair valu estim rel base case
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
vaccin add layer competit protect
intellectu properti cost advantag merck
scenario analysi show minor varianc henc low
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within pipelin import driver
valuat keytruda cancer addit unknown
full impact biosimilar competit remicad
immunolog diseas weigh certainti
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
gener drug compani enorm cash
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
fda grown
primary-car diseas tend approv safe
drug drug highli need area cancer
insur compani steadili reduc
coverag follow-on drug forc drug firm push
true innov reduc power distribut
network lastli govern develop market
increasingli use compar effect program
aggress push price negoti
respons challeng merck strateg focu
toward unmet medic need increas probabl
success regulatori agenc support stronger
price power payer altern exist
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
omerck key drug januvia look potenti safer
diabet drug follow-on combin
drug drive futur growth
oth launch biosimilar competit immunolog
drug remicad continu caus drag
owhil major patent loss behind
compani sever major product face gener
competit next coupl year includ
zetia vytorin
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
omerck lack intern combin drug
keytruda could limit potenti keytruda
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
firm tend make sever bolt-on acquisit
year given merck made major
acquisit sinc schere plough deal
expect make larger acquisit near term
beyond acquisit expect steadi futur dividend
support pay-out ratio close rel
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica incom fund america
new jersey divis pension benefit
govern pension fund norway global
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani final
shift focu toward area specialti care away
primari care lead improv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
merck keytruda data continu shine
rais fve stock look under-valued jun
merck report strong keytruda data non-smal cell lung
cancer annual meet american societi
clinic oncolog support increas util
keytruda increas market share base data
increas keytruda project billion
ahead consensu expect billion lead
higher merck fair valu estim per share
continu view stock under-valued
keytruda opportun fulli reflect current
valuat keytruda efficaci lung cancer sever
type cancer support strong price power
merck present data keynot keytruda
monotherapi express patient
nsclc keytruda combin chemotherapi
squamou nsclc show drug reduc risk
death versu placebo respect
believ data drive merck market share first-lin
nsclc drive total market
immuno-oncolog drug billion previou
estim billion market segment expect
increas market adopt follow efficaci data
chang standard care nsclc set
expect merck take share bristol roch
astrazeneca base cross-trial comparison
support keytruda competit drug howev
expect major shift valuat compet firm
increas expect overal market
strong data compet drug cancer mitig
nsclc market share shift merck expect roch
tecentriq like gain next largest amount
market especi egfr mutat
segment competitor lack data follow
bristol opdivo plu yervoy strength
complet overview merck pipelin current
market product along analysi compani
posit within immuno-oncolog space pleas see
healthcar observ steadi pipelin off-set gener
threat secur pharma moat
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
polit driven difficult implement
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
buoy keytruda merck post solid share
merck report first-quart result slightli
consensu bottom-lin expect dont
expect meaning chang fair valu estim
still view stock under-valued invest
commun fulli appreci compani strong long-
term potenti merck abil show top-lin growth
quarter despit heavi competit virolog
franchis gener competit matur drug
reinforc view merck wide moat support
wide rang patent-protect drug
quarter strong gain immuno-oncolog drug
keytruda help mitig sale pressur older drug
lead overal oper growth year year
growth rate look like remaind year
keytruda grow sale larg lung cancer
continu base recent disclos keynot studi
expand lung cancer patient popul
lower express expect close growth
keytruda follow growth drug
expand indic overal expect merck gain
close third immuno-oncolog market
strong leadership lung cancer
keytruda continu perform well sever
merck older franchis face pressur slow
overal growth compani virolog franchis hiv
hepat pressur better-
posit competit drug gilead
dont expect merck regain traction hepat
transloc inhibitor hold potenti help
return merck hiv market beyond brand
competit headwind gener competit continu
weigh current result expect major
gener competit annual end
current year set rel minor gener pressur
follow three year
complet overview merck pipelin current
market product along analysi compani
posit within immuno-oncolog space pleas see
healthcar observ steadi pipelin off-set gener
threat secur pharma moat
merck bristol strong data reaffirm immuno
oncolog potenti merck leadership apr
annual meet american associ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cancer research clinic data emerg
reinforc merck lead posit largest immuno-
oncolog area first-lin non-smal cell lung cancer
nsclc dont expect major chang fair
valu estim base data continu view key
immuno-oncolog player merck bristol roch
under-valued addit impress clinic data
aacr bristol merck unmet medic
need area nsclc help reinforc like high demand
medic commun compani immuno-
oncolog drug strengthen firm wide moat
merck bristol report detail result
alreadi report posit top-lin data nsclc
keytruda opdivo respect expect modest
chang market share expect merck
gain slightli better posit expect merck hold
lead posit first-lin nsclc market share
data merck
surviv patient regardless express level
clearli signific improv also bristol report
posit progress free surviv data clearli
signific opdivo plu bristol drug yervoy
versu chemotherapi patient high tumor mutat
burden tmb importantli signific side effect
bristol immuno-oncolog combin lower
chemotherapi dont know surviv data yet
studi bristol comment surviv look
encourag howev merck gain first-mov
advantag bristol import surviv data
expect bristol gain first-lin nsclc
market potenti target patient best
bristol studi high tmb well
older patient less will endur side effect
despit neg stock price movement bristol
think stock price movement overreact
bristol opdivo yervoy still look well posit
sever cancer outsid nsclc project
repres close long-term sale particular
data melanoma renal cancer liver cancer support
leadership posit bristol nevertheless continu
expect merck overal leader immuno
oncolog support firm like lead posit
nsclc continu model strong sale roch
tecentriq lung cancer second merck note key
data still pend overal surviv data studi
combin tecentriq avastin chemotherapi
present near futur
epacadostat failur blow merck
merck announc phase
studi epacadostat combin
keytruda metastat melanoma fail
combin unabl improv progression-fre surviv
keytruda alon unlik improv overal surviv
well hazard ratio trend toward
benefit compani halt studi expect
signific impact fair valu estim
weve previous point epacadostat
key driver compani valuat impact merck
mute compani alreadi establish
leader immuno-oncolog keytruda monotherapi
process launch gather data
combin keytruda variou regimen
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
